That which does not kill me makes me stronger; combining ERK 1/2 pathway inhibitors and BH 3 mimetics to kill tumour cells and prevent acquired resistance
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Oncogenic mutations in RAS or BRAF can drive the inappropriate activation of the ERK 1/2. In many cases, tumour cells adapt to become addicted to this deregulated ERK 1/2 signalling for their proliferation, providing a therapeutic window for tumour‐selective growth inhibition. As a result, inhibition of ERK 1/2 signalling by BRAF or MEK 1/2 inhibitors is an attractive therapeutic strategy. Indeed, the first BRAF inhibitor, vemurafenib, has now been approved for clinical use, while clinical evaluation of MEK 1/2 inhibitors is at an advanced stage. Despite this progress, it is apparent that tumour cells adapt quickly to these new targeted agents so that tumours with acquired resistance can emerge within 6–9 months of primary treatment. One of the major reasons for this is that tumour cells typically respond to BRAF or MEK 1/2 inhibitors by undergoing a G 1 cell cycle arrest rather than dying. Indeed, although inhibition of ERK 1/2 invariably increases the expression of pro‐apoptotic BCL 2 family proteins, tumour cells undergo minimal apoptosis. This cytostatic response may simply provide the cell with the opportunity to adapt and acquire resistance. Here we discuss recent studies that demonstrate that combination of BRAF or MEK 1/2 inhibitors with inhibitors of pro‐survival BCL 2 proteins is synthetic lethal for ERK 1/2‐addicted tumour cells. This combination effectively transforms the cytostatic response of BRAF and MEK 1/2 inhibitors into a striking apoptotic cell death response. This not only augments the primary efficacy of BRAF and MEK 1/2 inhibitors but delays the onset of acquired resistance to these agents, validating their combination in the clinic. Linked Articles: This article is part of a themed section on Emerging Therapeutic Aspects in Oncology. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2013.169.issue‐8
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ERK1/2 signalling also represses BIM and PUMA transcription by destabilising FOXO3A14–17.”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156 · cited 1×
“Both the phase II trial and interim analysis of the phase III trial comparing vemurafenib to dacarbazine reported confirmed clinical responses in around 50% of patients, compared with 5% for dacarbazine (Chapman et al., 2011; Sosman et al., 2012).”
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · cited 2×
“…2010); activating MEK1 mutation (Wagle et al., 2011; Greger et al., 2012); expression of BRAFV600E splice variants that preferentially dimerize (Poulikakos et al., 2011); BRAF amplification (Shi et al., 2012); and activating RAS mutations (Nazarian et al., 2010; Greger et al., 2012; Su et al.,…”
BackgroundKuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A., Green, D. R., & Newmeyer, D. D. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.003 · Cited by 1,185 · cited 8×
“Obatoclax can induce cell death through various mechanisms, some of which are consistent with BH3 mimetic activity but some of which do not require BAX and BAK (Konopleva et al., 2008).”
BackgroundInfluentialMeloche, S., & Pouysségur, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210414 · Cited by 1,091 · cited 3×
“Acquired resistance to BRAF inhibitors can arise through multiple mechanisms, such as switching to ARAF or CRAF (Montagut et al., 2008; Villanueva et al., 2010); up-regulation of alternative MEK1/2 activators (Johannessen et al., 2010); activating MEK1 mutation (Wagle et al., 2011; Greger et al.,…”
BackgroundInfluentialMaurer, U., Charvet, C., Wagman, A. S., Dejardin, E., & Green, D. R. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.02.009 · Cited by 881
Wilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70261-8 · Cited by 876 · cited 2×
“In a phase I study of relapsed or refractory lymphoid malignancies (including CLL) 22% of patients had partial responses (Wilson et al., 2010), and in a phase I study of relapsed or refractory CLL 35% of patients exhibited partial responses (Roberts et al.”
BackgroundModelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655
Research works printed but not linked: 124
- Andrews M, 2012, Colorectal cancer promoted in a melanoma patient receiving dabrafenib (GSK2118436) in combination with MEK1/2 inhibitor trametinib (GSK1120212), Pigment Cell Melanoma Res, 25, 842
- 10.1111/j.1365-2133.2012.11155.x · DOI · Paper page
- 10.1158/1078-0432.CCR-11-1344 · DOI · Paper page
- 10.1158/0008-5472.CAN-08-2819 · DOI · Paper page
- 10.1038/cdd.2008.148 · DOI · Paper page
- 10.1002/ijc.24604 · DOI · Paper page
- Basile KJ, 2012, Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B‐RAF melanoma cells, Am J Cancer Res, 2, 726
- 10.1007/s10637-010-9392-8 · DOI · Paper page
- 10.1038/nrc3297 · DOI
- 10.1038/nrd3847 · DOI · Paper page
- 10.1126/science.286.5443.1358 · DOI · Paper page
- 10.1038/onc.2010.616 · DOI
- 10.1093/emboj/18.19.5321 · DOI · Paper page
- 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0 · DOI · Paper page
- 10.1056/NEJMoa1208958 · DOI · Paper page
- 10.1038/nrd839 · DOI · Paper page
- 10.1080/10428190902748971 · DOI
- Chapman P, 2012, Development of colonic adenomas and gastric polyps in BRAF mutant melanoma patients treated with vemurafenib, Pigment Cell Melanoma Res, 25, 847
- 10.1056/NEJMoa1103782 · DOI · Paper page
- 10.1016/j.molcel.2010.01.025 · DOI · Paper page
- 10.1038/onc.2009.52 · DOI · Paper page
- 10.1056/NEJMra025195 · doi:10.1056/nejmra025195 · Paper page
- 10.1158/2159-8290.CD-11-0341 · DOI · Paper page
- 10.1371/journal.pmed.0040316 · DOI · Paper page
- 10.1016/S0092-8674(00)80405-5 · DOI · Paper page
- 10.1158/1535-7163.MCT-07-0231 · DOI · Paper page
- 10.1038/nature00766 · DOI · Paper page
- 10.1016/j.ccr.2006.08.027 · DOI · Paper page
- 10.1074/jbc.M101714200 · DOI · Paper page
- 10.1016/S0960-9822(00)00728-4 · DOI · Paper page
- 10.1038/nrc969 · DOI · Paper page
- 10.1073/pnas.0905833106 · DOI · Paper page
- 10.1128/MCB.02061-07 · DOI · Paper page
- 10.1038/sj.emboj.7601723 · DOI · Paper page
- 10.1038/sj.onc.1203076 · DOI · Paper page
- 10.1093/annonc/mdq258 · DOI · Paper page
- Fox W, 1999, Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946‐1986, with relevant subsequent publications, Int J Tuberc Lung Dis, 3, S231
- 10.1074/jbc.M306614200 · DOI · Paper page
- 10.1172/JCI28281 · DOI · Paper page
- 10.1038/382511a0 · DOI · Paper page
- 10.1073/pnas.081074898 · DOI · Paper page
- 10.1158/2159-8290.CD-12-0386 · DOI · Paper page
- 10.1016/j.cell.2012.02.015 · DOI · Paper page
- 10.1158/1535-7163.MCT-11-0989 · DOI · Paper page
- 10.1097/JTO.0b013e3181e8b3a3 · DOI · Paper page
- 10.1038/nature08833 · DOI · Paper page
- 10.1158/1535-7163.MCT-11-1010 · DOI · Paper page
- 10.1158/1078-0432.CCR-11-0563 · DOI · Paper page
- 10.1016/j.cell.2009.12.040 · DOI · Paper page
- 10.1073/pnas.050586197 · DOI · Paper page
- 10.1073/pnas.1008990107 · DOI · Paper page
- 10.1016/j.bbamcr.2003.08.009 · DOI · Paper page
- 10.1158/1078-0432.CCR-11-1491 · DOI · Paper page
- 10.1089/108729002760220798 · DOI · Paper page
- 10.1016/j.ccr.2006.10.006 · DOI · Paper page
- 10.1158/0008-5472.CAN-07-1919 · DOI · Paper page
- 10.1038/leu.2011.287 · DOI · Paper page
- 10.1200/jco.2010.28.15_suppl.3534 · DOI · Paper page
- 10.1073/pnas.0606176103 · DOI · Paper page
- 10.1111/pcmr.12092 · DOI · Paper page
- 10.1074/jbc.M301010200 · DOI · Paper page
- 10.1016/j.ccr.2012.10.009 · DOI · Paper page
- 10.1126/scisignal.2001752 · DOI · Paper page
- 10.1038/onc.2012.160 · DOI
- 10.1038/cdd.2012.21 · DOI
- 10.1158/1535-7163.TARG-11-A229 · DOI
- 10.1158/0008-5472.CAN-07-6787 · DOI · Paper page
- 10.1038/nature09626 · DOI · Paper page
- 10.1182/blood-2008-02-137943 · DOI · Paper page
- 10.1200/JCO.2009.22.5748 · DOI · Paper page
- 10.1038/nature03579 · DOI · Paper page
- 10.1007/s00280-010-1265-5 · DOI
- 10.1016/j.lungcan.2011.05.005 · DOI · Paper page
- 10.1002/cncr.27790 · DOI
- 10.1126/science.278.5338.687 · DOI · Paper page
- 10.1038/nature08902 · DOI · Paper page
- 10.1158/1535-7163.MCT-08-0973 · DOI
- 10.1158/0008-5472.CAN-12-1365 · DOI
- 10.1152/ajpcell.1999.277.4.C652 · DOI · Paper page
- 10.1200/JCO.2011.34.7898 · DOI · Paper page
- 10.1111/j.1432-0436.2006.00075.x · DOI
- 10.1158/1078-0432.CCR-11-3090 · DOI · Paper page
- 10.1074/jbc.274.43.31108 · DOI · Paper page
- 10.1101/gad.836800 · DOI · Paper page
- 10.1146/annurev.med.59.090506.202405 · DOI · Paper page
- 10.1158/0008-5472.CAN-09-4471 · DOI · Paper page
- 10.1038/cddis.2011.137 · DOI
- 10.1074/jbc.M109907200 · DOI · Paper page
- 10.1074/jbc.M800271200 · DOI · Paper page
- 10.1038/onc.2010.380 · DOI · Paper page
- 10.1038/ncomms1727 · DOI · Paper page
- 10.1016/S0960-9822(00)00310-9 · DOI · Paper page
- 10.1158/1535-7163.MCT-08-0431 · DOI · Paper page
- 10.1038/nature04304 · DOI · Paper page
- 10.1158/1541-7786.MCR-11-0394 · DOI
- 10.1056/NEJMoa1105358 · DOI · Paper page
- 10.1158/0008-5472.CAN-11-1875 · DOI · Paper page
- 10.1038/nrm2952 · DOI · Paper page
- 10.1158/1535‐7163.MCT‐12‐0949 · DOI · Paper page
- 10.1074/jbc.274.49.34859 · DOI · Paper page
- 10.1056/NEJMoa1014209 · DOI · Paper page
- 10.1016/j.semcancer.2012.02.013 · DOI · Paper page
- 10.1056/NEJMc0904160 · DOI · Paper page
- 10.1158/0008-5472.CAN-07-5836 · DOI · Paper page
- 10.1158/0008-5472.CAN-08-3934 · DOI · Paper page
- 10.1101/gad.294104 · DOI · Paper page
- 10.1128/MCB.24.23.10340-10351.2004 · DOI
- 10.1016/j.ccr.2010.11.023 · DOI · Paper page
- 10.1200/JCO.2010.33.2312 · DOI · Paper page
- 10.1038/onc.2011.497 · DOI · Paper page
- 10.1158/0008-5472.CAN-10-4351 · DOI · Paper page
- 10.1158/1078-0432.CCR-07-0665 · DOI · Paper page
- 10.1126/scitranslmed.3000758 · DOI · Paper page
- 10.1038/onc.2008.335 · DOI · Paper page
- 10.1128/MCB.16.10.5546 · DOI · Paper page
- 10.1093/carcin/bgs330 · DOI · Paper page
- 10.1677/erc.1.0978 · DOI · Paper page
- 10.1038/ncb1676 · DOI · Paper page
- 10.1182/blood-2009-07-233304 · DOI · Paper page
- 10.1158/1078-0432.CCR-06-1150 · DOI · Paper page
- 10.1084/jem.20060353 · DOI · Paper page
- 10.1016/S0092-8674(00)81382-3 · DOI · Paper page
- 10.1038/sj.cdd.4401937 · DOI · Paper page
- 10.1038/sj.leu.2405098 · DOI · Paper page
Cited by
The role of MAPK signalling pathways in the response to endoplasmic reticulum stress
Darling, N. J., & Cook, S. J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.01.009 · Cited by 399
Self-citationSale, M. J., Minihane, E., Monks, N. R., Gilley, R., Richards, F. M., Schifferli, K. P., Andersen, C. L., Davies, E. J., Vicente, M. A., Ozono, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12409-w · Cited by 80
Self-citation
Metadata
- Authors
- Sale, M. J., & Cook, S. J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2013-07-26
- Volume
- 169
- Issue
- 8
- Pages
- 1708-1722
- ISSN
- 0007-1188
- 1476-5381
- Cited by
- 20
- References
- 23
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.